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(Mip1p) led to the development of many successful yeast 
models, enabling to study the phenotype of putative 
pathogenic mutations. In a group of patients with suspi-
cion of mitochondrial pathology, we identified five novel 
POLG sequence variants, four of which (p.Arg869Ter, 
p.Gln968Glu, p.Thr1053Argfs*6, and p.Val1106Ala), 
together with one previously known but uncharacterised 
variant (p.Arg309Cys), were amenable to modelling in 
yeast. Familial analysis indicated causal relationship of 
these variants with disease, consistent with autosomal 
recessive inheritance. To investigate the effect of these 
sequence changes on mtDNA replication, we obtained the 
corresponding yeast mip1 alleles (Arg265Cys, Arg672Ter, 
Arg770Glu, Thr809Ter, and Val863Ala, respectively) 
and tested their effect on mitochondrial genome stabil-
ity and replication fidelity. For three of them (Arg265Cys, 
Arg672Ter, and Thr809Ter), we observed a strong, par-
tially dominant phenotype of a complete loss of functional 
mtDNA, whereas the remaining two led to partial mtDNA 
depletion and significant increase in point mutation fre-
quencies. These results show good correlation with the 
severity of symptoms observed in patients and allow to 
establish these variants as pathogenic mutations.
Introduction
Mitochondria arose from an α-proteobacterial symbiont in 
an endosymbiosis event approximately 1.5 billion of years 
ago (Dyall et al. 2004; Gray et al. 1999). These organelles 
are present in all aerobic eukaryotic cells, and are crucial 
for energy production, and many other processes, like Fe-S 
cluster synthesis, Ca2+ homeostasis, fatty acid oxidation 
and apoptosis (Aon et al. 2014; Kasahara and Scorrano 
2014; Stehling et al. 2014).
Abstract Replication of the mitochondrial genome 
depends on the single DNA polymerase (pol gamma). 
Mutations in the POLG gene, encoding the catalytic subu-
nit of the human polymerase gamma, have been linked to a 
wide variety of mitochondrial disorders that show remark-
able heterogeneity, with more than 200 sequence variants, 
often very rare, found in patients. The pathogenicity and 
dominance status of many such mutations remain, how-
ever, unclear. Remarkable structural and functional con-
servation of human POLG and its S. cerevisiae ortholog 
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As a legacy of their endosymbiotic origin, mitochon-
dria are the only organelles in animal and fungal cells con-
taining their own DNA (mtDNA). Unlike nuclear DNA 
(nDNA), there are hundreds or even thousands of copies of 
mtDNA in a single cell. Usually all the copies of mitochon-
drial DNA are identical (homoplasmy), but mitochondrial 
DNA molecules with different sequence variants (poly-
morphic or pathogenic) can coexist with wild-type mtDNA 
(heteroplasmy) (Aanen et al. 2014).
Human mitochondrial DNA is a circular double-stranded 
molecule encoding 13 proteins which are subunits of the 
respiratory chain complexes, 22 tRNAs and 2 rRNAs (Holt 
et al. 2014; Mishra and Chan 2014). Therefore, the vast 
majority of 1000–1500 proteins necessary for the proper 
functioning of the organelle and cellular regulation of 
mtDNA integrity and copy number are encoded by nDNA 
and transported into the mitochondrion. The reciprocal 
influence of nuclear gene expression and processes located 
in mitochondria is referred to as intergenomic communica-
tion (Spinazzola and Zeviani 2007).
Mitochondrial diseases are a group of heterogenic mul-
tiorgan disorders, particularly affecting tissues with high 
energy requirement, like muscles and nerves. They may be 
caused by mtDNA mutations, nuclear gene mutations (for 
example in genes encoding subunits of respiratory chain 
complexes), or by mutations in nuclear genes encoding 
proteins involved in mtDNA replication and stability, hav-
ing a secondary effect on mitochondrial DNA amount and 
quality (Spinazzola and Zeviani 2007).
Replication of human mitochondrial DNA depends 
entirely on nuclear-encoded proteins. The only DNA pol-
ymerase present in human mitochondria is polymerase γ, 
a member of the type A family of DNA polymerases. It 
functions as a heterotrimer and consists of a catalytic subu-
nit (POLG) encoded by the POLG gene (15q26.1), and 
two accessory subunits (POLG2) encoded by the POLG2 
(17q23.3) gene. POLG is a 140 kDa protein composed 
of 1239 aa (the N-terminal 25 aa form the mitochondrial 
import signal and are cut off during import) and is capable 
of replicating DNA on its own; the interaction with POLG2 
increases polymerase fidelity and processivity. Three 
domains can be distinguished in the catalytic subunit: the 
exonuclease domain with the proofreading activity (26–418 
aa), the polymerase domain (756–1239 aa), and the linker 
region (419–755 aa) located between the two domains 
which is a platform for direct interaction with one of the 
accessory subunits (Graziewicz et al. 2006; Longley et al. 
2005; Stumpf and Copeland 2011). An alternative localiza-
tion of the POLG domain boundaries was proposed after 
the publication of the crystal structure of the Pol γ holo-
enzyme, in which the exonuclease domain encompasses 
amino acids 171–440, the linker region covers aa 476–785, 
and the polymerase domain is split into two and comprises 
amino acids 441–475 and 786–1239 (Lee et al. 2009). 
The exact domain sequence boundaries are still subject to 
dispute.
Mutations in the POLG gene may disrupt mtDNA rep-
lication, leading to the formation of multiple mtDNA dele-
tions, to depletion (pathological decrease of the mtDNA 
copy number), or to a combination of these defects, which 
in turn disrupts the mitochondrial function and energy pro-
duction (Stumpf and Copeland 2011). POLG mutations 
can, therefore, lead to a spectrum of mitochondrial diseases 
with dominant or recessive type of inheritance, which can 
be divided into three main groups: sporadic/familial pro-
gressive external ophthalmoplegia (PEO) (OMIM #157640 
and #258450), adult-onset ataxia (OMIM #607459), and 
Alpers syndrome (OMIM #203700). Mitochondrial dis-
eases attributed to mutations in POLG show a remarkable 
heterogeneity with, according to the Human DNA Poly-
merase Gamma Mutation Database (http://tools.niehs.nih.
gov/polg/), more than 200 variants known to date, many of 
them rare.
The budding yeast is widely used as a genetic model 
system to study mtDNA stability and mutagenesis. Unlike 
most other microorganisms, S. cerevisiae can stably exist 
both in a haploid and a diploid state. Recessive mutations 
can be conveniently isolated and manifested in haploid 
strains, while complementation tests can be performed in 
the diploids. Heterozygous mutants allow the effects of 
dominant alleles to be observed. The most useful feature of 
these microorganisms in the study of mitochondrial func-
tion is that respiratory deficient mutants are viable and the 
presence of mtDNA is optional. The respiratory deficient 
phenotype can be easily observed as a formation of the so-
called petite colonies on fermentative media, and lack of 
growth on respiratory-only media (Ephrussi and Slonimski 
1955). S. cerevisiae is, therefore, an excellent model for the 
study of communication between nuclear and mitochon-
drial genetic systems. Due to the evolutionary conserva-
tion of some features of the mitochondrial system, like the 
mtDNA polymerase, they also may be used as a model for 
research on human mutations and their role in mtDNA rep-
lication (Barrientos 2003; Baruffini et al. 2007; Foury and 
Kucej 2002; Graziewicz et al. 2006; Longley et al. 2005; 
Stumpf and Copeland 2011; Lodi et al. 2015).
The yeast mitochondrial DNA polymerase (Mip1) is a 
nuclear-encoded protein, essential for the maintenance of 
the mitochondrial genome. It is orthologous to the human 
polymerase γ, and in spite of the evolutionary distance, 
its domain structure and amino acid sequence are essen-
tially conserved (Foury 1989; Ropp and Copeland 1996). 
A yeast strain with its native mitochondrial DNA polymer-
ase replaced by the human polymerase γ is viable and even 
maintains the functional mitochondrial genome essentially 
as efficiently as the wild type yeast (Qian et al. 2014). The 
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Mip1 protein consists of four domains: the exonuclease-
like domain, the linker region, the polymerase-like domain 
and the C-terminal domain. The polymerase and exonucle-
ase domains are highly similar to their human equivalents. 
Unlike human Pol γ, Mip1 does not have any accessory 
subunits, and does not form a heterotrimer complex (Lucas 
et al. 2004; Yakubovskaya et al. 2006). Consequently, the 
linker region is not well conserved, and its sequence shows 
no significant similarity to that of the human ortholog. 
Another difference is the presence in Mip1 of a C-terminal 
domain, absent in human POLG (Viikov et al. 2011, 2012). 
In spite of those differences between yeast and human 
mtDNA polymerases, it is still possible to model many of 
the polymerase γ mutations found in patients with mito-
chondrial diseases in the yeast protein. As it is with POLG, 
even a single amino acid substitution in one of the con-
served domains of Mip1 can lead to a severe mitochondrial 
deficiency phenotype. Combining comparable phenotypes 
with easy and fast analysis makes budding yeast an excel-
lent model for examining pathologies of human polymerase 
γ (Barrientos 2003; Baruffini et al. 2006, 2007, 2011, 2014; 
Baruffini and Lodi 2010; Foury and Kucej 2002; Lodi 
et al. 2015; Stuart et al. 2006; Stricker et al. 2009; Stumpf 
et al. 2010; Stumpf and Copeland 2011, 2013, 2014; Szc-
zepanowska and Foury 2010).
In search of new possibly pathogenic variants which 
can be modelled in S. cerevisiae, POLG sequence analy-
sis was conducted for 60 patients with mitochondrial 
disease. Known well-characterised variants and novel 
sequence changes located in regions poorly conserved 
between human and yeast were rejected. We chose four 
previously undescribed variants for further study. The 
c.2604 C>T (p.Arg869Ter), c.2901C>G (p.Gln968Glu), 
c.3155_3156delCA (p.Thr1053Argfs*6) and c.3316 T>C 
(p.Val1106Ala) are located in the polymerase domain. In 
addition, one previously known substitution c.924C>T 
(p.Arg309Cys) located in the exonuclease domain was also 
included in the study. This mutation was reported once and 
only vaguely mentioned in the original work, additionally 
symptoms observed in both patients differ (Amiot et al. 
2009). A novel nonsense mutation p.Arg869Ter in the poly-
merase domain serves as a control of the usefulness of our 
yeast model.
Materials and methods
Population analysis of novel POLG mutations
Analysis of the presence of the mtDNA deletions was con-
ducted by long range PCR as described previously (Kier-
daszuk et al. 2009). For patients with confirmed multiple 
mitochondrial DNA deletions, depletion or strong clinical 
indication, we performed POLG sequence analysis similar 
to (Filosto et al. 2003) (primer sequences are provided in 
Online Resource 1).
Reactions were performed in 25 µl final volume con-
taining 0.16 µM of each of the forward and reverse primer, 
0.4 mM of dNTPs, 1 U of Taq polymerase (A&A Biotech-
nology) and 100 ng of DNA. PCR conditions were 94° for 
5 min, followed by 35 cycles of 94° for 1 min, appropri-
ate annealing temperature (64° for POLG1_1, 6, 7, 8, 9, 10 
C and 58° for POLG1_2, 3, 4, 5, 11, 12) for 1 min, 72° 
for 1 min and final elongation at 72° for 7 min. Sequenc-
ing was performed in the Laboratory of DNA Sequencing 
and Oligonucleotide Synthesis, Institute of Biochemistry 
and Biophysics, Polish Academy of Sciences. Sequences 
were compared with the POLG reference sequence (Ref-
Seq NG_008218.1). The novel sequence variants were 
deposited in GenBank with accession numbers KP783508 
(p.Gln968Glu), KP783509 (p.Arg290Cys), KP783511 
(p.Arg869Ter), KP783513 (p.Val1106Ala), and KP783512 
(p.Thr1053Argfs*6). We have also deposited sequence for 
p.Arg309Cys (KP783510) variant since it was not present 
in the GeneBank.
To estimate the frequency of the analysed POLG 
sequence variants in the Polish population, we designed and 
performed PCR–RFLP or high-resolution melting (HRM) 
tests on control DNA samples isolated from adults without 
neuromuscular disorders who gave their informed consent 
for genetic testing. HRM is a technique based on real-time 
PCR which utilizes differences in melting temperature of 
amplicons based on their nucleotide composition and ena-
bles to distinguish samples even with single-nucleotide 
substitution (Montgomery et al. 2010). Control samples 
for which test results were inconclusive were subsequently 
sequenced. In the case of p.Arg309Cys, a restriction site 
for the HhaI enzyme disappears in the POLG1_3 frag-
ment, whereas for p.Thr1053Argfs*6 and p.Val1106Ala 
restriction sites for BaeGI and HincII, respectively, disap-
pear in the POLG1_10 fragment. The digestion reactions 
were performed as follows: 5 µl of PCR product, 10 U of 
enzyme (New England Biolabs), 2 µl of buffer 2 (HhaI) or 
3.1 (BaeGI and HincII), water up to 20 µl and incubated 
overnight in 37°.
To test the population frequencies of variants 
p.Arg869Ter and p.Gln968Glu, two pairs of primers for 
HRM test were designed (HRM869F/R and HRM968F/R, 
respectively). HRM reactions were prepared in 10 µl 
final volume containing MasterMix 1x (Roche), 3 mM 
(p.Arg869Ter) or 3.5 mM (p.Gln968Glu) MgCl2, 0.15 µM 
of each of the forward and reverse primer, and 60 ng of 
DNA. Initial denaturation for 10 min at 95° (4.8°/s) was 
followed by 45 cycles of 10 s at 95° (4.8°/s), 15 s at 60° 
(p.Arg869Ter) or 67° (p.Gln968Glu) (2.5°/s), 20 s at 72° 
(4.8°/s). Melting curves were determined as follows: 95° 
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for 5 min (4.4°/s), 40° for 3 min (2.2°/s), 60° for 1 s (1°/s) 
and heating up to 95° (0.02°/s) with 25 acquisitions per 1°.
To verify reciprocal in trans localization of vari-
ants p.Arg309Cys and a second undescribed variant in 
patient AI2, we cloned a POLG fragment using primers 
H3POLG1_3F and S1POLG1_3R and pGEM-T Easy Vec-
tor into XL10-Gold chemocompetent E. coli (Stratagene).
Yeast strains, plasmids and media
S. cerevisiae strains used in the research were two deriva-
tives of W303, differing in the mating type: W303-1B 
(Chiron et al. 2005) (MATa ade2-1 leu2-3, 112 ura3-1 
trp1-1 his3-11, 15 can1-100) and CW04 (Chiron et al. 
2005) (MATα ade2-1 leu2-3, 112 ura3-1 trp1-1 his3-11, 
15 can1-100). Strain ∆mip1 was derived from CW04 by 
deleting the MIP1 gene with the KanMX4 cassette (MATa 
ade2-1 leu2-3, 112 ura3-1 trp1-1 his3-11, 15 can1-100 
mip1::KanMX4). D273-10B/51 (MATα ade5, [rho0]) 
(Groudinsky et al. 1981) was used as a tester strain for the 
mitochondrial genome integrity.
The wild-type MIP1 gene with approximately 300 bp 
of upstream and downstream sequences was amplified 
using primers mip1l and mip1r (Online Resource 1) and 
cloned into centromeric plasmids YCplac33 (URA3) and 
YCplac111 (LEU2) (Gietz and Sugino 1988) using the 
SLIC method (Li and Elledge 2007). The resulting con-
structs were named YCplac33MIP1 and YCplac111MIP1, 
respectively. Before transformation, all the constructs 
were verified by sequencing. For overexpression of mutant 
alleles, new constructs based on the pRS425 vector (Chris-
tianson et al. 1992) were created, by subcloning mutated 
sequences using the SLIC method (Li and Elledge 2007). 
All the constructs were verified by sequencing.
The following media were used in this work: YP 
medium consisted of 1 % yeast extract (Bioshop) 2 % Pep-
tone (Bioshop) and 40 mg/l adenine (Sigma). YP medium 
was supplemented with 2 % glucose (YPD) or 2 % glyc-
erol (YPG). SC medium consisted of 6.7 g/l YNB without 
amino acids (Bioshop) supplemented with an adequate 
amount of drop-out mix (Formedium™) according to the 
manufacturer’s instructions. The SC media were sup-
plemented with 2 % glucose or 2 % glycerol. For evalu-
ating the petite frequency, YPDG medium was used: 1 % 
yeast extract (Bioshop), 2 % Peptone (Bioshop), 40 mg/l 
adenine, 2 % glycerol and 0.1 % glucose. YPAEG-ery and 
YPAEG-oli media were used to determine frequencies of 
point mutations in mutant strains; they consisted of: 1 % 
yeast extract (Bioshop) 2 % Peptone (Bioshop) and 40 mg/l 
adenine, 2 % glycerol and 25 mM potassium phosphate 
buffer (pH 6.5) and 3 g/l erythromycin (Sigma) or 3 mg/l 
oligomycin (Sigma), respectively. For solid media, 2 % 
agar (Bioshop) was added.
Construction of mip1 mutant strains
The mip1 mutant alleles were obtained by site-directed 
mutagenesis of the wild-type MIP1 gene cloned into 
YCplac111 (YCplac111MIP1), using the double primer 
method of Zheng et al. (2004). The following mutated 
alleles were created (Table 2): Arg265Cys, Arg672Ter, Arg-
770Glu, Arg770Gln, Thr809Ter, Val863Ala (see Online 
Resource 1 for primer sequences). The W303/∆mip1 dip-
loid, obtained by mating W303-1B and ∆mip1 strains, was 
transformed with both the wild-type YCplac33MIP1 and a 
mutated version of YCplac111mip1 plasmids. This provided 
a functional wild-type MIP1 allele, allowing to maintain 
mtDNA (provided by the W303-1B parental strain) in the 
∆mip1 background. This diploid was subsequently sporu-
lated, and haploid spores bearing both plasmids and the 
genomic ∆mip1 gene deletion were selected using replica 
plating (-Ura, -Leu, G418 selection media). Subsequently, 
the YCplac33MIP1 URA3 plasmid carrying the wild-type 
MIP1 gene was removed by counterselection on 5-FOA 
plates (Sikorski and Boeke 1991), leaving the mutated vari-
ant of Mip1p as the only polymerase γ in the cells.
When the amino acid in the human POLG sequence was 
different from the corresponding residue in yeast Mip1p, 
in addition to the allele with the wild-type yeast residue 
replaced with the mutated human POLG amino acid (puta-
tive pathological allele), a second strain was created, with 
the wild-type human residue introduced into the yeast 
sequence, resulting in the humanized allele. The activ-
ity of the mutated protein was then compared both to the 
wild-type yeast sequence, and to the humanized variant of 
Mip1p.
Determining the effect of mutations on oxidative 
growth phenotype
To define oxidative growth phenotype, 10 µl of 10−1, 10−2, 
10−3 and 10−4 dilutions of liquid culture of each strain 
(starting from OD600 = 1) was spotted on YPD and YPG 
plates and incubated at 30° (normal temperature) or 37° 
(elevated temperature) for 3 days.
Determination of mtDNA stability in yeast mip1 
mutants
Single colonies of strains obtained in the 5-FOA counterse-
lection procedure were grown in liquid YPD medium at 
30° or 37°. After 48 h of incubation, cells were diluted to 
OD600 = 1 and around 300–500 colonies were plated on 
YPDG medium. Colonies were incubated for 60 h at 30° 
and 37°. Subsequently, both petite and rho+ colonies were 
counted using the tetrazolium test (Ogur et al. 1957) (using 
2 mg/ml of TTC).
Hum Genet 
1 3
For heteroallelic strains, appropriate selective SC 
medium with 2 % glucose instead of YPD was used for ini-
tial incubation. This was necessary to prevent the loss of 
plasmids in the preculture.
For each strain, at least 20 independent experiments 
were performed. Statistical significance of observed differ-
ences was evaluated using the T test (two-tailed, unequal 
variance) for p < 0.05 confidence levels.
To confirm that the respiratory deficient phenotype was 
due to changes in mtDNA, the petite strains were crossed 
to a wild-type rho0 tester strain (D273-10B/51), and the 
resulting diploids assayed for respiratory growth on YPG 
plates.
Detection of mtDNA in yeast petite cells
The presence of mtDNA in yeast strains displaying the 
petite phenotype was assessed by staining of DNA in fixed 
cells with the Hoechst 3324 dye (Invitrogen), followed by 
fluorescent microscopy imaging as described previously 
(Puchta et al. 2010).
RT-PCR for MIP1 mRNA in yeast
Total cellular RNA was extracted according to the method 
described previously (Schmitt et al. 1990). RNA sample 
was treated with DNAse (Roche) in the presence of RNAse 
inhibitor (Ribolock, Thermo) in the buffer recommended 
by the manufacturer. DNA-free RNA was then extracted 
with phenol/chloroform/octanol (25:24:1), precipitated 
from the aqueous phase by ethanol/sodium acetate (pH 5.2) 
and dissolved in water. 5 µg of DNA-free RNA was reverse 
transcribed by Maxima™ Reverse Transcriptase (Thermo 
Scientific) according to the manufacturer’s instructions. 
Reactions without reverse transcriptase (RT-) were used as 
controls to test for genomic DNA contamination. cDNA 
was then amplified by PCR using the rtMipL and rtMipshR 
or rtMipL and rtMiploR primer pairs (Online Resource 1).
Quantification of point mutation accumulation in yeast 
mtDNA
To evaluate point mutation frequencies, two independent 
series of experiments consisting of 10 repeats were con-
ducted. Each colony was grown in 3 ml of YPG for 48 h 
at 30°. Subsequently, 6–8 × 107 colonies were plated on 
YPAEG-ery medium and incubated at 30° for 9 days. 
Simultaneously, for each YPG culture, 50 µl of a 10−5 dilu-
tion was plated on a YPG plate to establish the exact num-
ber of colony-forming units in the culture.
The mutation frequencies in Table 2 are shown as 
the mean count of EryR colonies per 108 CFU. The 
Mann–Whitney U test was used to establish statistical sig-
nificance for this experiment.
For the OliR experiment, the same protocol was used, 
except that instead of 3 g/l erythromycin, 3 mg/l oligomy-
cin was added to the medium and the number of colonies 
plated on YPAEG-oli plate was approximately 3–5 × 107 
CFU.
Results
Novel POLG variants in mitochondrial disease patients
In a search for previously undescribed variants, POLG 
coding sequence analysis was conducted for 60 patients 
with clinical diagnosis of myopathy (OMIM # 251900) 
(n = 18), encephalomyopathy (n = 5), PEO (OMIM 
#157640 and #258450) (n = 4), PEO and myopathy 
(n = 3), encephalopathy (n = 3), polyneuropathy (n = 2), 
myoclonic epilepsy associated with ragged-red fibres 
(MERRF) (OMIM #545000) (n = 2), Kearns-Sayre syn-
drome (OMIM #530000) (n = 1), myopathy, encepha-
lopathy, lactic acidosis and stroke-like episodes (MELAS) 
(OMIM #540000) (n = 1), mitochondrial neurogastro-
intestinal encephalopathy (MNGIE) (OMIM #613662) 
(n = 1), sensory ataxic neuropathy, dysarthria and oph-
thalmoparesis (SANDO) (OMIM #607459) (n = 2), gen-
eral suspicion of mitochondrial disease (n = 15) or Alp-
ers syndrome (OMIM #203700) (n = 3). Sequencing of 
the POLG gene in these patients, followed by in silico 
translation, revealed 1 poorly uncharacterised and 5 previ-
ously unreported sequence changes located in the regions 
conserved between yeast and human (c.924 C>T/p.Arg-
309Cys and c.867 C>T/p.Arg290Cys—proband from 
family A, c.2604 C>T/p.Arg869Ter—proband from fam-
ily B, c.2901 C>G/p.Gln968Glu—proband from family 
C, c.3155_3166delCA/p.Thr1053Argfs*6—proband from 
family D and c.3316 T>C/p.Val1106Ala—proband from 
family E). None of the novel variants were present in the 
Human Polymerase Gamma Mutation Database, NCBI 
dbSNP (Sherry 2001), the 1000 genomes project (Genomes 
Project Consortium 2012), or in the Exome Variant Server 
database (http://evs.gs.washington.edu/EVS/). These vari-
ants, along with the poorly characterised p.Arg309Cys, 
were therefore selected for further investigation, and their 
sequences deposited in GenBank (accession numbers are 
listed in “Materials and methods”).
Patients’ clinical presentation
The results of sequence analysis, clinical and molecu-
lar evaluation of the four patients carrying previously 
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unreported POLG variants and one with the known, but 
poorly characterised variant, are summarized in Table 1. 
Proband from family A (AI2) (Fig. 1a) is a 54-year-old 
woman with SANDO syndrome and positive family his-
tory (her brother presented similar symptoms). From the 
age of 31, she suffered from progressive external ophthal-
moplegia, ptosis, dysarthria, weakness of upper and lower 
limbs and sensory ataxic neuropathy. Additionally, mental 
retardation was diagnosed. Nerve conduction studies indi-
cated axonal sensory and motor neuropathy. MRI showed 
brain atrophy. Skeletal muscle biopsy disclosed ragged-red 
fibres on light microscopy examination. Analysis of mito-
chondrial DNA revealed multiple deletions in muscle tis-
sue. Along with the p.Arg309Cys variant, patient AI2 also 
had another previously unknown sequence change c.867 
C>T (p.Arg290Cys) for which, due to a low level of simi-
larity in this position between POLG and Mip1 (Fig. 2c), 
creating a yeast model was impractical. According to Poly-
Phen-2 (Adzhubei et al. 2010), a software tool which pre-
dicts possible impact of a single amino acid substitution on 
the function of human proteins, both these variants found 
in patient AI2 are probably damaging, with a score of 
Table 1  Clinical symptoms, mtDNA and POLG sequence analysis in patients
Bold text indicates novel variants
a Compared to the POLG reference sequence (RefSeq NG_008218.1)
b Muscle tissue
c Liver tissue
Proband POLG sequence variantsa Result of mtDNA analysis Clinical diagnosis
AI2 c.867 C>T (p.Arg290Cys)/c.924 C>T (p.Arg309Cys) Multiple deletionsb SANDO
BII1 c.2243 G>C (p.Trp748Ser)/c.2604 C>T (p.Arg869Ter) Depletionc Alpers syndrome
CII1 c.925 G>T (p.Arg309Leu)/c.2901 C>G (p.Gln968Glu) Multiple deletionsb PEO
DII1 c.2243 G>C (p.Trp748Ser)/c.3155_3156delCA (p.Thr1053Argfs*6) Depletionc Alpers syndrome
EII2 c.2243 G>C (p.Trp748Ser)/c.3316 T>C (p.Val1106Ala) No lesions detected SANDO
A
p.Arg290Cys/
p.Arg309Cys
p.Arg309Cys
/wt
p.Arg290Cys/
p.Arg309Cys
I
II
1 2
1
C
p.Arg309Leu/
p.Gln968Glu
p.Arg309Leu
/wt
p.Gln968Glu
/wt
I
II
III
1
1
1 2
p.Trp748Ser
/wt
p.Val1106Ala
/wt
p.Trp748Ser/
p.Val1106Ala
p.Val1106Ala
/wt
I
II
1 2
1 2
E
p.Trp748Ser
/wt
p.Arg869Ter
/wt
p.Trp748Ser/
p.Arg869Ter
II 1
I 1 2
DB
p.1053fsThrArg*6
/wt
p.Trp748Ser
/wt
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Fig. 1  POLG variant distribution analysis in patients and their 
families. a Proband (I2) and her brother (I1) are both affected and 
have one known, but poorly characterised and one novel variant 
(p.Arg290Cys/p.Arg309Cys), whereas the proband’s healthy son (II1) 
is a carrier of the p.Arg309Cys variant. b Proband (II1) died at the 
age of 2.5 years due to liver failure caused by valproic acid adminis-
tration. He carried heterozygous p.Trp748Ser mutation and heterozy-
gous novel variant p.Arg869Ter. His parents (I1 and I2) are heterozy-
gous carriers of either pathogenic mutation p.Trp748Ser (I1), or the 
novel variant p.Arg869Ter (I2). c Proband (II1) carries heterozygous 
pathogenic mutation p.Arg309Leu and heterozygous novel variant 
p.Gln968Glu. Her children (III1 and III2) are unaffected heterozy-
gous carriers of pathogenic mutation p.Arg309Leu (III1), and the 
novel variant p.Gln968Glu (III2). The presence of p.Gln968Glu in 
the proband’s father (I1) was excluded, but due to the lack of biologi-
cal material we were unable to perform the analysis for the presence 
of the p.Arg309Leu mutation. d The proband (II1) died at the age of 
3.5 years after liver failure due to valproic acid administration. Both 
parents (I1 and I2) have either the novel p.Thr1053Argfs*6 (I1) vari-
ant or the known pathogenic mutation p.Trp748Ser (I2). e Proband 
(II2) carries heterozygous pathogenic mutation p.Trp748Ser together 
with heterozygous novel variant p.Val1106Ala. Her father (I1) is a 
carrier of the known pathogenic mutation p.Trp748Ser, whereas both 
her mother (I2) and brother (II1) have heterozygous novel variant 
p.Val1106Ala. All heterozygous family members are asymptomatic. 
Since the analysis of familial distribution of POLG variants present in 
families a–e indicates that all the probands are compound heterozy-
gotes in trans, an autosomal recessive mode of inheritance is sug-
gested
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1.00. SIFT Human Protein DB tool also predicts that both 
variants p.Arg290Cys and p.Arg309Cys are not tolerated 
(SeqRep = 0.92) (Ng and Henikoff 2001). The proband’s 
brother (AI1) carries both p.Arg309Cys and p.Arg290Cys 
variants present in the proband AI2.
The proband from family B (BII1) was without any 
symptoms at infancy. At the age of 12 months, he became 
progressively ataxic and recurrent convulsions appeared, 
developing quickly to severe epileptic encephalopathy. 
Soon after introduction of anticonvulsant valproic acid 
administration, a fulminant liver failure was observed and 
the patient died at the age of 2.5 years. Severe mitochon-
drial depletion found in the liver tissue on autopsy (0.08 %, 
while the threshold for diagnosing depletion is set at <30 % 
of the normal mtDNA level) was in agreement with the 
clinical suspicion of Alpers syndrome. POLG sequenc-
ing revealed two in trans variants, one known pathogenic 
p.Trp748Ser substitution (Palin et al. 2010; Van Goethem 
et al. 2004), and a novel variant p.Arg869Ter.
Proband from family C (CII1) (Fig. 1c) is a 53-year-
old woman with progressive external ophthalmoplegia 
and negative family history. At the age of 38, she observed 
impaired eye movements and ptosis. Nerve conduction 
studies were normal, and electromyography indicated 
myogenic changes. Cardiological assessment revealed no 
abnormalities. Skeletal muscle biopsy disclosed ragged-
red fibres on light microscopy, and multiple abnormal 
mitochondria with paracrystalline inclusions on electron 
microscopy examination. Multiple mtDNA deletions were 
present in muscle tissue. POLG sequencing revealed a 
known p.Arg309Leu (Lamantea et al. 2002) mutation and 
a novel variant p.Gln968Glu, predicted to be not tolerated 
by SIFT (SeqRep = 0.97), and probably damaging with a 
score of 0.992 according to PolyPhen2.
In the proband from family D (DII1) (Fig. 1d), a psy-
chomotor retardation and muscle hypotonia were observed 
since 2 months of age, and autistic behaviour was observed 
during early chilhood. At the age of 3 years, the patient was 
given valproic acid due to episodes of unconsciousness and 
abnormal EEG pattern and responded suddenly with an 
acute liver failure. He died 6 months later before the quali-
fication for liver transplantation was completed. Severe 
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Fig. 2  Modelling human POLG variants using the S. cerevisiae 
ortholog—Mip1p. a Schematic representation of POLG and Mip1 
protein primary structure, with locations of the studied human POLG 
variants and the corresponding residues in S. cerevisiae Mip1p. The 
exonuclease domain is shown shaded light grey and the polymerase 
domain is shaded dark grey. Sequence of the linker region is not con-
served. Blocks I, II, and III in the exonuclease domain, and A, B, and 
C in the polymerase domain are the regions of highest sequence con-
servation. b Alignment of the mitochondrial DNA polymerase amino 
acid sequences of selected vertebrate and yeast species in the regions 
of human variants selected for yeast modelling. Conserved residues 
(>0.5 consensus identity) are highlighted, arrows point to residues 
changed in the variant alleles under study. c Alignment of the mito-
chondrial DNA polymerase amino acid sequences of selected verte-
brate and yeast species in the region around human Arg290 residue 
(marked with an asterisk), where lack of conservation between verte-
brate and yeast sequences makes modelling of the Arg290Cys variant 
impractical
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depletion of mtDNA was found in the liver section taken 
at autopsy (3.4 %, ref. >30 %), as in the case of the patient 
BII1. In the POLG sequence, in addition to the known 
p.Trp748Ser mutation, a novel variant p.Thr1053Argfs*6 
was found.
In spite of normal developmental milestones, the 
proband from family E (EII2) (Fig. 1e) started to have 
walking difficulties at the age of 13 years. Her condition 
deteriorated, and she developed ataxic gait and dysar-
thria. Two years later, she developed action-exacerbated 
myoclonus. When last seen at 15 years, she had no oph-
thalmoparesis. Nerve conduction studies showed sensory-
motor polyneuropathy of lower limb nerves. We did not 
detect mtDNA deletions in a DNA sample isolated from 
peripheral blood. Since muscle tissue was not available, 
the decision to sequence POLG was undertaken based on 
the patient’s clinical presentation, and indicated that she 
was a compound heterozygote p.Trp748Ser/p.Val1106Ala. 
The novel variant (p.Val1106Ala) is designated as not tol-
erated (SIFT SeqRep = 0.98) and possibly damaging with 
a score of 0.85 (PolyPhen2). Interestingly, another amino 
acid change (valine to isoleucine) in the same position was 
described previously as probably pathogenic (Horvath et al. 
2006).
Each of the novel variants coexisted in the patient 
with a known pathogenic recessive mutation, and all the 
patients’ parents were healthy; therefore, we suspected that 
all the variants, if pathogenic, were also recessive. For all 
the patients, DNA samples isolated from other members 
of their families were also available. To confirm in trans 
localization of novel versus known variants in patients AI2, 
BII1, CII1, DII1 and EII2, we performed family studies, 
and in one case cloning.
Familial and population study
To verify reciprocal localization of novel and known vari-
ants in patients, we acquired DNA samples from their fam-
ily members, and amplified and subsequently sequenced 
the relevant POLG fragments (Fig. 1). In three families 
(B, D and E), the proband’s parents were each carrier of 
one of the two pathogenic/possibly pathogenic variants. In 
the case of proband AI2, the parents’ DNA was unavail-
able, but POLG sequence analysis of her son (AII1) proved 
him to be the carrier of the known, but poorly character-
ised p.Arg309Cys variant. Her symptomatic brother (AI1) 
had both variants p.Arg290Cys and p.Arg309Cys found in 
the proband. Additionally, we performed cloning of POLG 
alleles in patient AI2, which further confirmed that she 
was a compound heterozygote. The family of patient CII1 
did not give consent to obtain their DNA from peripheral 
blood, but agreed to perform buccal swabs. Both her chil-
dren are heterozygous carriers of the pathogenic (CIII1-p.
Arg309Leu) or possibly pathogenic (CIII2-p.Gln968Glu) 
variant. The presence of the novel variant p.Gln968Glu in 
her father (CI1) was ruled out, but due to a low yield of 
DNA extraction, we were not able to confirm the presence 
of the p.Arg309Leu mutation. Thus, we confirmed that in 
all the affected individuals, the two variants were in trans.
The population frequency of all novel variants was 
estimated using PCR–RFLP or HRM tests. Because the 
population frequency of p.Arg309Cys was not previously 
assessed, we also conducted PCR–RFLP test for this vari-
ant. None of the analysed POLG sequence variants were 
found in 320 chromosomes of healthy adults, which means 
that the population frequency of each variant is signifi-
cantly lower than 1 %.
The analysis of familial distribution and frequency in 
the general population suggests that the analysed POLG 
sequence changes are probably pathogenic and inherited in 
a recessive manner.
Modelling the putative pathogenic mutations in yeast
To gain some insights into the effects of the novel variants 
in the human polymerase γ using the well established and 
accessible S. cerevisiae model, we first aligned the amino 
acid sequences of human POLG and its yeast ortholog 
Mip1p, and identified the residues that were mutated in 
patient sequences (Fig. 2). Of the 5 residues, three (Arg309, 
Arg869, and Val1106) were conserved in the yeast Mip1p. 
The site of the frameshift mutation p.Thr1053Argfs*6 also 
corresponds to a block of a nearly complete amino acid 
sequence identity. The Gln968 residue, also in a conserved 
region, corresponds to Arg770 in the yeast protein. In this 
case, in addition to the mutated allele (with Glu in this posi-
tion), we also created the humanized allele (Arg770Gln).
The mutant mip1 alleles were created by site-directed 
mutagenesis and introduced into the ∆mip1 background 
on centromeric (low copy number) vectors, as described in 
“Materials and methods”. The plasmid shuffling strategy 
was used to maintain functional mtDNA owing to the pres-
ence of the wild-type MIP1 gene on an URA3 vector, which 
could subsequently be eliminated by 5-FOA counterselec-
tion (Sikorski and Boeke 1991).
Influence of mip1 mutations on respiratory growth 
phenotype in the yeast model
Growth on a non-fermentable carbon source (glycerol or 
ethanol) is the fastest and simplest method to examine res-
piratory function in S. cerevisiae strains. Among the five 
tested strains carrying yeast equivalents of putative patho-
genic mutations, three exhibited a severe respiratory defi-
ciency. Mutants Arg265Cys, Arg672Ter and Thr809Ter 
were unable to support growth on glycerol at 30° (Fig. 3). 
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Growth of the remaining strains did not differ from the 
wild-type. Incubation at a restrictive temperature (37°) con-
tributed to an even more severe phenotype of mutants which 
were unable to grow on glycerol (Arg265Cys, Arg672Ter, 
Thr809Ter), causing slower growth even on a medium with 
fermentable carbon source. The elevated temperature did 
not significantly affect the rest of the tested strains.
Determination of petite frequencies in strains with mip1 
mutations
Petite mutants of S. cerevisiae are unable to grow on non-
fermentable carbon sources and form only small anaerobic 
colonies in the presence of glucose. While this phenotype 
can result from a point mutation in mtDNA or a mutation 
in a nuclear gene, most often it is caused by a complete 
loss (rho0) or extensive deletions (rho−) of mtDNA. Petite 
colonies appear at a low (1–5 %) rate spontaneously in cul-
tures grown on fermentable carbon sources. Mutations in 
nuclear genes encoding proteins involved in mitochondrial 
function often result in a marked increase in the frequency 
of petite generation (Contamine and Picard 2000; Lipinski 
et al. 2010).
All the strains carrying mip1 alleles corresponding to 
the modelled human mutations show increased petite fre-
quencies in comparison to the one with the wild-type MIP1 
(Fig. 4a; Table 2). Furthermore, mutations Arg265Cys, 
Arg672Ter, Thr809Ter, which cause a complete respiratory 
deficiency, lead to a complete loss of functional mtDNA in 
the tested strains.
For the Arg770Glu mutation, petite accumulation is 
significantly (p < 0.05) higher than in its humanized allele 
mip1Arg770Gln and in the wild-type version of the pro-
tein (5.6, 1.6, and 1.4 % at 30°, respectively). Further-
more, there is no significant difference between wild-type 
Mip1p (1.4 % petite) and humanized Arg770Gln (1.6 %). 
Petite frequency of the strain carrying the Val863Ala allele 
(5.3 %) is approximately three times higher than in the 
wild-type strain at 30°, and this difference is statistically 
significant (p < 0.05).
To confirm that the observed respiratory negative phe-
notype was related to the loss of functional mtDNA, 
petite colonies from the strains carrying the Arg265Cys, 
Arg672Ter and Thr809Ter variants (50 colonies each) were 
crossed to a wild-type rho0 tester, and the resulting diploids 
assayed for respiratory growth. This test confirmed that in 
all the petite colonies there was no functional mtDNA left 
(rho−/rho0). Due to the presence of nonfunctional residual 
mitochondrial genome fragments in rho− mtDNA, it is not 
practical to perform quantitative analysis of mtDNA levels 
in yeast cells using PCR-based methods. For the strains car-
rying the Arg265Cys, Arg672Ter and Thr809Ter variants, 
DNA staining with Hoechst dye followed by fluorescent 
microscopy imaging revealed that, unlike in the wild-type 
control, extranuclear DNA signal is mostly absent, suggest-
ing that they are essentially rho0 (Online Resource 2).
Fig. 3  Respiratory growth of S. cerevisiae strains bearing the wild 
type and mutated alleles of MIP1. Fermentative growth was tested 
on YPD medium (YP with 2 % glucose) at 30° and 37°. Respiratory 
growth was tested by plating the strains on YPG medium (YP with 
2 % glycerol) and incubation at 30° and 37°. Each strain was spotted 
in 10−1, 10−2, 10−3 and 10−4 dilutions (starting from OD600 = 1). The 
pictures were taken after 3 days of incubation. a Fermentative (YPD) 
and respiratory (YPG) growth at normal temperature (30°). All the 
strains grow on the fermentable carbon source (YPD), although the 
strains bearing the Arg265Cys, Arg672Ter and Thr809Ter variants 
show slightly slower growth. These strains are not able to grow on 
medium with the nonfermentable carbon source (YPG) (b). The same 
growth assay as in (a), but carried out at the elevated temperature 
(heat stress, 37°). The phenotype of strains bearing the Arg265Cys, 
Arg672Ter and Thr809Ter variants is even more pronounced at the 
elevated temperature, and the growth defect on the fermentable car-
bon source is more apparent. The strains that are not affected at nor-
mal temperature do not show a respiratory deficiency at 37° either
 Hum Genet
1 3
The severe phenotype of the Arg265Cys, Arg672Ter and 
Thr809Ter variants raised the possibility that these mutations 
abolished the expression of the MIP1 gene, and thus were 
equivalent to transcriptional nullomorphs. We performed an 
RT-PCR assay on total RNA isolated from the strains car-
rying the Arg265Cys, Arg672Ter and Thr809Ter variants as 
the only MIP1 alleles, and found no apparent change com-
pared to the wild-type control, thus confirming that these 
mutations do not interfere with the expression of the MIP1 
gene, at least on mRNA level (Online Resource 3).
Determination of petite frequencies in heteroallelic 
strains
To determine the dominance/recessivity of the mutations, 
we assayed the frequency of petite formation in heteroal-
lelic yeast strains bearing each of the mutant alleles as well 
as the wild-type MIP1 allele (Fig. 4b; Table 2). A hemial-
lelic strain containing the empty YCplac111 vector as well 
as the vector carrying the wild type MIP1 (vector/MIP1) 
was also used as a control to normalise the allele dosage and 
differentiate between antimorphy and haploinsufficiency. 
The petite frequency in the hemiallelic strain is slightly, 
but significantly (p < 0.05) higher than in the MIP1/MIP1 
strain, and this effect is more pronounced at the elevated 
temperature (37°). MIP1 haploinsufficiency is evident when 
a diploid strain heterozygous for the ∆mip1 allele is used 
(Baruffini et al. 2006). The haploid deletant strain with plas-
mid-borne wild-type and mutant MIP1 alleles used in this 
study is clearly less sensitive to haploinsufficiency.
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Fig. 4  Mitochondrial genome stability in yeast strains carrying 
MIP1 alleles corresponding to the POLG variants found in human 
patients. a Frequencies of petite mutants in strains carrying the wild-
type MIP1 or mutated mip1 alleles in the homoallelic setting (as the 
only MIP1 allele on a centromeric plasmid). Mutations Arg265Cys, 
Arg672Ter, and Thr809Ter lead to a complete loss of functional 
mtDNA (100 % petites) and the petite frequency in Mip1Val863Ala 
strain is three times higher than in the wild type strain. The Arg-
770Glu mutation significantly increases petite accumulation in com-
parison to either the wild type, or humanized (Arg770Gln) allele. 
There is no significant difference between the humanized Arg-
770Gln and the wild-type allele. b Frequencies of petite mutants in 
the pure wild-type (MIP1/MIP1), hemiallelic (vector/MIP1) and het-
eroallelic (MIP1/mip1) strains, with both alleles expressed from low 
copy number (centromeric) plasmids. In heteroallelic strains with 
Arg265Cys/MIP1, Arg672Ter/MIP1 and Thr809Ter/MIP1 alleles, 
petites accumulate at a significantly higher frequency than in the 
hemiallelic (vector/MIP1) strain; nevertheless, they still retain >80 % 
of functional mtDNA. Petite frequency in the Val863Ala/MIP1 shows 
a slight (but significant at p < 0.05) difference compared with the 
hemiallelic (vector/MIP1) at 30°, but not at 37° (not marked on the 
graph). The Arg770Glu/MIP1 heteroallelic strain shows no significant 
difference compared to either the hemiallelic (vector/MIP1) or the 
humanized strain. Only the strongly significant differences (p < 0.01) 
were marked with asterisks in this panel for clarity. c Frequencies 
of petite mutants resulting from the overexpression (on the multi-
copy pRS425 plasmid) of mutant alleles (in the background of the 
wild-type MIP1 on a low copy number vector). For Arg265Cys and 
Arg672Ter variants, no significant difference was observed between 
the low copy number and multicopy vectors, but for the Thr809Ter 
allele the petite frequency was significantly higher when the mutated 
allele was on a multicopy plasmid, suggesting an antimorphic char-
acter of the mutation. The T test (two-tailed, unequal variance) was 
used to assess the statistical significance, *p < 0.05, and **p < 0.01. 
ns not significant. Numerical data can be found in Table 2
▸
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In the Val863Ala/MIP1 strain, the petite frequency was 
slightly, yet significantly (p < 0.05) higher than in the vec-
tor/MIP1 strain at 30°. No increase in petite frequency 
could be observed at the elevated temperature (37°). Even 
though the difference at 30° was statistically significant, 
the petite frequency in this heteroallelic strain remained 
low (well below 5 %); the dominant negative effect of this 
allele is thus negligible.
The petite accumulation frequency for the heteroallelic 
strain Arg770Glu/MIP1 strain, as well as for the human-
ized Arg770Gln/MIP1, was not significantly elevated above 
the level observed in the hemiallelic vector/MIP1 control 
at either temperature; this mutation is, therefore, recessive.
Strains heteroallelic for the three mutations that showed 
the most severe phenotype (complete respiratory deficiency 
and loss of functional mtDNA) in the monoallelic setting, 
Arg265Cys/MIP1, Arg672Ter/MIP1, and Thr809Ter/MIP1, 
accumulated petites at a much higher frequency than the 
hemiallelic vector/MIP1 control strain (at both tempera-
tures), although they still retained >80 % of functional 
mtDNA. These alleles thus have a partially dominant neg-
ative effect on the mtDNA replication process (Fig. 4b; 
Table 2). To verify whether this effect is dependent on allele 
dosage, we also constructed strains carrying the mutant 
alleles on multicopy (episomal) plasmids, and the wild-type 
allele on a centromeric plasmid (Fig. 4c). For Arg265Cys 
and Arg672Ter, no significant difference was observed 
between the low copy number and multicopy vectors, for 
the Thr809Ter allele; however, increasing the copy number 
of the mutated variant resulted in a significantly (p < 0.01) 
more pronounced phenotype of the heteroallelic strain, sug-
gesting a true antimorphic character of this mutation.
Frequency of mtDNA point mutations in the yeast 
model
Two of the five mutated mip1 alleles, Arg770Glu and Val-
863Ala, showed only a partial decrease in overall mtDNA 
stability (measured by the frequency of petite colony for-
mation), whereas the humanized Arg770Gln variant was 
indistinguishable from the wild type in that aspect. No 
effect on the respiratory growth was observed in these 
three strains. To test whether the replicative function of the 
mitochondrial DNA polymerase in these strains was not 
affected in a more subtle way, we performed experiments 
assessing the point mutation rates in mtDNA.
Quantification of point mutation accumulation in 
mtDNA is based on estimating the frequencies of spontane-
ous oligomycin- (OliR) and erythromycin-resistant (EryR) 
mutants that result from substitutions in mitochondrial 
genes encoding the ATPase subunits or the large subunit 
rRNA, respectively. This assay can indicate changes in the 
fidelity of mtDNA replication, such as defects in the proof-
reading activity of the mitochondrial DNA polymerase.
Two mutations (Arg770Glu, Val863Ala) and the human-
ized allele (Arg770Gln) were examined in comparison to 
the wild-type strain (Table 2; Fig. 5). The strain carrying 
the Val863Ala allele showed a slight, but still statistically 
significant (p < 0.05, Mann–Whitney U test) increase in 
the frequency of both OliR and EryR mutations. The effect 
of the Arg770Glu allele, on the other hand, was more pro-
nounced, and significantly (p < 0.05) higher both in com-
parison with the wild-type MIP1, and with the Arg770Gln 
humanized variant (differences between the humanized 
allele and the wild type version were not significant). 
Table 2  Analysis of mtDNA stability and point mutations in mutant yeast strains carrying MIP1 alleles corresponding to the POLG variants 
found in human patients
Statistical significance calculated compared to the wild-type Mip1 for homoallelic strains, except for Arg770Glu, where the humanized Arg-
770Gln variant was used as reference
For the heteroallelic strains, statistical significance was calculated compared to the hemiallelic vector/MIP1 strain
* p < 0.05, ** p < 0.01
Variant in H. sapiens Mutation in  
S. cerevisiae
Domain Petite frequency (%) OliR/108CFU EryR/108CFU
Homoallelic Heteroallelic with wt MIP1
30° 37° 30° 37°
– wt MIP1 – 1.4 ± 0.8 2.8 ± 1.5 1.0 ± 0.7 1.3 ± 0.4 0.7 ± 0.3 0.5 ± 0.18
Hemiallelic vector/MIP1 1.7 ± 0.8 2.5 ± 0.7
p.Arg309Cys Arg265Cys exo 100 ± 0** 100 ± 0** 16.2 ± 4.3** 17.5 ± 4.6** – –
p.Arg869Ter Arg672Ter pol 100 ± 0** 100 ± 0** 15.9 ± 4.0** 18 ± 3.8** – –
p.Gln968Glu Arg770Glu pol 5.6 ± 1.8* 7 ± 2.9* 2.7 ± 1.8 3.0 ± 1.7 15 ± 7.8* 7.4 ± 1.4*
Arg770Gln (humanized) 1.6 ± 1.0 2.0 ± 0.9 1.5 ± 1.2 1.7 ± 0.5 3.8 ± 1.8 1.6 ± 0.33
p.Thr1053Argfs*6 Thr809Ter pol 100 ± 0** 100 ± 0** 13.9 ± 5.8** 16.0 ± 5.9** – –
p.Val1106Ala Val863Ala pol 5.3 ± 1.7* 4.7 ± 1.4* 3.4 ± 1.7* 2.9 ± 1.5 3.6 ± 2.7* 3.4 ± 0.1*
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Interestingly, this substitution (as well as Val863Ala) is 
located in the polymerase domain (Table 2). It has to be 
noted, however, that the effect observed for this variant, 
while statistically significant (p < 0.05), is far less evident 
than that reported for an MIP1 allele devoid of the correc-
tive exonuclease domain activity (exo−), where the EryR 
mutation frequency increased by 550-fold (Stumpf et al. 
2010).
Discussion
To date, over 200 POLG sequence changes are known, and 
for the vast majority their pathogenicity remains unclear. 
Since most variants are classified as pathogenic only on the 
basis of their presence in the patient, there are only a few 
well-documented POLG mutations. Here, we present an in-
depth analysis of 5 POLG variants—4 novel and 1 known 
but poorly characterised, found in patients with mitochon-
drial disorder symptoms: p.Arg309Cys, p.Arg869Ter, 
p.Gln968Glu, p.Thr1053Argfs*6 and p.Val1106Ala, com-
bining familial and population studies with a functional 
study in a yeast model. Since the population frequency 
of all the analysed variants is lower than 1 %, it is highly 
probable that they are not polymorphic sequence changes 
but true pathogenic mutations.
As it is often the case for the severe recessive mitochon-
drial disorders caused by POLG mutations (like the Alpers 
syndrome) (Chan et al. 2009; Euro et al. 2011; Mancuso 
et al. 2004; Wiltshire et al. 2008; Wong et al. 2008), the 
affected individuals are compound heterozygotes. In our 
study, all the novel POLG variants in the patients coexist 
with another known mutation. Pedigree analysis, together 
with the results of the general population study, strongly 
suggests that p.Arg309Cys, p.Arg869Ter, p.Gln968Glu, 
p.Thr1053Argfs*6 and p.Val1106Ala are indeed pathogenic 
variants inherited in a recessive manner. To verify these 
assumptions, we used the yeast S. cerevisiae as a model for 
studying phenotypes of the 4 novel and 1 known but poorly 
characterised POLG mutations that occur in sequence 
regions conserved between yeast and human orthologs. The 
validity of using S. cerevisiae as a model in studying known 
human pathogenic POLG mutations was demonstrated in 
many cases (Barrientos 2003; Baruffini et al. 2006, 2007, 
2011, 2014; Baruffini and Lodi 2010; Foury and Kucej 
2002; Lodi et al. 2015; Stuart et al. 2006; Stumpf et al. 
2010; Stumpf and Copeland 2011, 2013, 2014), including 
cases where no other evidence for causation was available 
(Stumpf et al. 2010), yet studies simultaneously report-
ing new human mutations in a patient cohort and analysing 
the phenotype of the corresponding yeast strains are still 
very rare (Baruffini et al. 2011). Furthermore, for all the 
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Fig. 5  Replication fidelity, expressed as point mutation frequencies in 
yeast strains carrying MIP1 alleles corresponding to the POLG vari-
ants found in human patients. Oligomycin- and erythromycin-resistant 
mutant frequencies were calculated as a fraction of the rho+ cells plated 
on the respiratory (YPG) medium for the mip1 alleles that did not cause 
a complete loss of mtDNA stability. a Frequencies of mutations (in 
mitochondrial genes encoding the ATPase subunits) resulting in oligo-
mycin resistance. Black circles correspond to the antibiotic resistant col-
onies on individual plates. b Frequencies of mutations (in the mitochon-
drial gene encoding the large subunit rRNA) resulting in erythromycin 
resistance. Open circles correspond to the antibiotic resistant colonies 
on individual plates. Horizontal lines indicate the mean value of medi-
ans from two independent experimental repetitions (10 plates each). In 
both assays, the strain carrying the Val863Ala mutation showed a sig-
nificant increase in the point mutation frequency. The effect of the Arg-
770Glu allele on mutation frequencies was even more pronounced, and 
significantly elevated either in comparison to the wild-type MIP1, or 
to the Arg770Gln humanized variant, whereas differences between the 
humanized variant and the wild-type allele were not statistically sig-
nificant. Mann–Whitney U test was used to assess the statistical signifi-
cance, *p < 0.05, and **p < 0.01. ns not significant. Numerical data can 
be found in Table 2
Hum Genet 
1 3
modelled mutations, we observed phenotypes consistent 
with the clinical status of the human patients.
All the mutant strains in our yeast model display a phe-
notype that in some aspects differs significantly from the 
wild type. Arg770Glu and Val863Ala, corresponding to 
human p.Gln968Glu and p.Val1106Ala POLG variants, 
respectively, are located in the polymerase domain and 
show a rather mild defect of mtDNA stability (measured 
by a moderate increase in petite frequency). Additionally, 
in both these strains, we observed an increase in the fre-
quency of point mutations (measured by the rates of spon-
taneous erythromycin and oligomycin resistant colony 
formation). This correlates with the observations made in 
patients—proband EII2 carrying the p.Val1106Ala variant 
has no detectable mtDNA lesions, in spite of polyneuropa-
thy symptoms, whereas in the muscle tissue of proband 
CII1 carrying the p.Gln968Glu variant, multiple DNA dele-
tions are evident, but the phenotype is still relatively mild 
(PEO). Correspondingly, the decrease in mtDNA stability 
and increase in the frequency of point mutations were more 
pronounced in the yeast strain carrying the Arg770Glu 
variant than in the one with the Val863Ala allele. The rel-
evance of the relatively mild increase in the frequency of 
point mutations we observed for these variants in the yeast 
model for the human pathology is, however, not evident. 
In yeast, a mutant deficient in the exonuclease function of 
Mip1p (Exo−) shows an increase in mtDNA point muta-
tions of about 550-fold (Stumpf et al. 2010) that is orders 
of magnitude larger than the effect of the Arg770Glu and 
Val863Ala alleles (about 15-fold at best). Also, increases in 
mtDNA mutation rate in the exonuclease deficient POLG 
mouse model (Trifunovic et al. 2004; Vermulst et al. 2007) 
lead to a premature ageing phenotype, but do not result in 
marked physiological effects in young animals. The effects 
of changes that involve mtDNA point mutation frequencies 
are likely to be cumulative, and thus difficult to compare 
between different model systems.
The other two polymerase domain mutations are 
Arg672Ter and Thr809Ter, corresponding to human vari-
ants p.Arg869Ter and p.Thr1053Argfs*6, respectively. 
These two alleles encode protein variants with a sequence 
truncated in the middle of the polymerase domain, due to 
the presence of a premature STOP codon. Expectedly, in 
the monoallelic yeast strains, we observe a total loss of 
Mip1 activity, resulting in a complete loss of functional 
mtDNA. Accordingly, compound heterozygote patients 
carrying these variants exhibited a severe Alpers syndrome 
(Table 1). In the yeast model, in the heteroallelic setting 
(with a mutated allele and the wild-type allele present in 
the same strain), they show a partially dominant effect, with 
a significant, albeit not complete, loss of mtDNA stability 
(Fig. 4b; Table 2) compared to a hemiallelic control. In the 
case of Thr809Ter, the partially dominant effect shows an 
allele dosage dependency (Fig. 4c), as increasing the copy 
number of the mutated allele by expressing it from a mul-
ticopy plasmid results in a further increase in petite colony 
formation, suggesting that this mutation is antimorphic.
While it is difficult to speculate about the exact molec-
ular mechanism of the observed defect without in-depth 
biochemical experiments, there are several possible mech-
anisms that could explain the disruptive effect of these 
mutations, resulting in a partially dominant negative phe-
notype. The truncated proteins could disrupt replication 
by competing for the binding of substrates or other protein 
factors essential for replication. Similar dominant nega-
tive phenotypes of mip1 alleles modelling putative human 
pathological variants were observed in previous studies 
(Stumpf et al. 2010). Interestingly, in familial analysis of 
human p.Arg869Ter and p.Thr1053Argfs*6 variants, no 
mitochondrial disorder symptoms were reported for het-
erozygous carriers of these alleles. The yeast model system 
appears to be more sensitive to perturbations in the mtDNA 
maintenance, as the lack of dominant mitochondrial dis-
ease in humans for alleles showing partial dominance in 
the yeast model was noted for at least five different cases 
(Stumpf et al. 2010). This could be explained by the lower 
copy number of mtDNA molecules per cell in yeast (about 
20–30 copies per cell, 50–100 fold less than in typical ver-
tebrate cells), and by the generally less robust character of 
the S. cerevisiae mitochondrial genome system, evidenced 
by the spontaneous generation of petites, evident even in 
wild-type strains and exacerbated by many different genetic 
and environmental factors (Contamine and Picard 2000; 
Lipinski et al. 2010). Alternatively, the carriers may suf-
fer from defects that are very mild compared to the severe 
pathology in affected compound heterozygotes, and thus 
are not evident in a typical familial study, or will develop a 
phenotype later in life. Low penetrance of pathologies such 
as migraines and neuropathies was suggested for simple 
heterozygous carriers of strongly pathogenic POLG vari-
ants (Tzoulis et al. 2006).
Interestingly, the only change in our analysis that is 
located in the exonuclease domain of the polymerase γ 
enzyme, p.Arg309Cys, corresponding to Arg265Cys in S. 
cerevisiae Mip1p, results in a yeast phenotype that is as 
severe as that of the truncated polymerase domain vari-
ants described in the previous paragraph, with a complete 
loss of functional mtDNA in the monoallelic strain and a 
significant increase in petite frequency in the heteroal-
lelic setting (Table 2; Fig. 4). Such a strong phenotype is 
unexpected for a simple substitution in the exonuclease 
domain, but stands in agreement with an original report of 
a patient with homozygous p.Arg309Cys variant, resulting 
from parents consanguinity, having way more severe phe-
notype than patient AI2 who is a compound heterozygote. 
Unlike proband AI2, the p.Arg309Cys homozygote started 
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showing symptoms during adolescence and besides PEO, 
ataxia, myopathy and dyshartia she also suffered from 
chronic intestinal pseudo-obstruction, epilepsy, strokes, 
hearing loss and pigmentary retinopathy, which led to her 
death at the age of 22 (Amiot et al. 2009). The phenotype 
of this variant is probably not related to an essential charac-
ter of the mutated residue, as a different substitution in the 
same position; Arg265Leu results only in a slight increase 
of petite frequency in yeast (Stumpf et al. 2010) and the 
human p.Arg309Leu allele in compound heterozygotes 
[patient CII1 in this study and one patient described previ-
ously (Lamantea et al. 2002)] causes only a relatively mild 
PEO phenotype. A previously described mip1 mutant com-
pletely deficient in the exonuclease function (Exo−) shows 
a massive increase in mtDNA point mutations (about 550 
fold), but only about 10 % petite frequency (Stumpf et al. 
2010). The severe phenotype of Arg265Cys could be due 
to the presence of an additional cysteine residue which can 
form undesirable disulphide bonds with another residue in 
the protein, and thus seriously alter the protein conforma-
tion (Farnum et al. 2014).
To summarize, the yeast model proved to be a valuable 
tool for the initial assessment of the phenotypic effect of 
novel or poorly characterised POLG variants found in human 
patients. The phenotypes of strains with mutations introduced 
into orthologous positions in regions conserved between 
human POLG and S. cerevisiae Mip1p are in good agree-
ment with clinical observations, as variants found in patients 
affected with the most severe forms of mitochondriopathy 
cause a complete loss of mtDNA stability in the monoallelic 
setting in yeast. The less severe variants corresponded to a 
partial loss of mtDNA stability (increase of petite formation 
rate) and/or increase in point mutation frequencies.
A recently developed alternative to orthologous mod-
elling is based on the expression of human POLG as the 
only mtDNA polymerase in yeast cells devoid of the native 
MIP1 gene, and is termed “humanized yeast” (Qian et al. 
2014). Both approaches have their merits and shortcom-
ings, and should be viewed as complementary rather than 
exclusive. Orthologous modelling is obviously unavail-
able when the variants occur in sequence regions that are 
not conserved between human and yeast polymerase γ 
sequences, like in case of proband AI2 carrying a novel 
variant p.Arg290Cys in addition to p.Arg309Cys. Using 
the human mitochondrial polymerase would overcome this 
particular limitation, but given the substantial differences in 
the structure and replication of yeast and human mtDNA, 
phenotypes observed for the variants of the human enzyme 
could also be related to changes in its capability to function 
in a heterologous environment.
Yeast Mip1 exhibits amazing sensitivity when used 
to model putative pathogenic variants of the orthologous 
human mtDNA polymerase. In the monoallelic setting, 
even the slight phenotypic effects manifest themselves as 
observable changes in the mitochondrial genome stability 
and fidelity of replication. As phenotypic tests involving 
very large numbers of individual colonies are feasible and 
economical in yeast, statistical significance of these obser-
vations can be reliably assessed. For the severe defects 
that cause complete loss of functional mtDNA, heteroal-
lelic strains can be easily constructed, and they provide 
valuable insights into the effects of these alleles, includ-
ing dominance/recessiveness relationships that can be cru-
cial for understanding the effects of corresponding human 
variants.
In conclusion, we proved that the mitochondrial DNA 
polymerase variants discovered in patients with mitochon-
drial disease, and modelled in yeast, have an influence on 
different aspects of the mitochondrial genome mainte-
nance, and are thus likely to be bona fide pathogenic muta-
tions. Our study also further confirms the utility of yeast 
Mip1p as a tool for studying human POLG variants.
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